Genetic Testing Miami: What Precision Genomics Reveals About Your Cardiovascular and Longevity Risk

Concierge medicine at PURE Executive Health & Wellness in Coral Gables uses physician-supervised genetic testing as part of a comprehensive executive health assessment to identify medically actionable variants in cardiovascular disease, hereditary cancer syndromes, and pharmacogenomics that your standard annual physical cannot detect. Research published in the International Journal of Molecular Sciences found clinically actionable variants in 6.2% of adults screened through a comprehensive genomic panel—most with no presenting symptoms. At PURE, those genetic findings are integrated with full-body MRI, VO2 max testing, epigenetic age clocks, and advanced cardiovascular imaging to produce a single, physician-interpreted longevity blueprint for executives and other high-performing adults in Miami who want more precise preventive care.

Most executives approaching their mid-forties have had their cholesterol checked dozens of times. They have completed annual physicals, perhaps even comprehensive executive workups at major medical centers. What almost none of them have done is examine the underlying genetic architecture that influences how their cardiovascular system will age, whether they are metabolizing medications correctly, and whether a pathogenic variant is silently shaping long-term cancer or cardiac risk—risks that can change prevention strategy, screening intervals, and medication choices well before disease appears.

That is not a gap in their physician’s effort. It is a structural limitation of how medicine was built. Standard care was designed to detect established disease. Precision genomics was built to find what comes decades before it, and this article explains where standard physicals fall short, how cardiovascular genetics, hereditary cancer testing, and pharmacogenomics add clinical value, and how those tools are incorporated into PURE’s executive assessments in Miami.

Why Standard Physicals Miss the Genetic Testing Picture

The conventional annual executive physical, even at premium institutions, is designed around a set of assumptions: measure what is measurable today, flag what is abnormal today, treat what is symptomatic today. That framework serves its purpose for acute care. For longevity medicine, it is the wrong instrument for the question being asked.

Familial hypercholesterolemia, caused by variants in the LDLR, APOB, or PCSK9 genes, affects approximately 1 in 250 adults and carries a cardiovascular risk 20 times higher than the general population if untreated. A standard lipid panel may flag elevated LDL, but it will not identify the genetic cause—which matters, because the clinical management of genetic hypercholesterolemia is substantially more aggressive than lifestyle-modifiable high cholesterol. Without genotyping, the distinction is invisible.

The same logic applies across the genome. A BRCA2 pathogenic variant confers a lifetime breast cancer risk exceeding 69% and a lifetime pancreatic cancer risk in the range of 5 to 10%—risks that change screening protocols, surveillance intervals, and potentially prophylactic surgical decisions. Yet this variant produces no signal on a comprehensive metabolic panel, an echocardiogram, or a chest X-ray. It is invisible to every instrument in the standard executive physical toolkit.

What the Research Shows: Actionable Findings in Asymptomatic Adults

According to research published in the International Journal of Molecular Sciences, a 2025 analysis of 3,972 individuals screened with whole-exome sequencing against the American College of Medical Genetics and Genomics (ACMG) v3.2 panel of 81 actionable genes identified medically actionable variants in 6.2% of the cohort. The distribution was clinically significant: cardiovascular disorders accounted for 3.0% of the population screened, cancer predisposition for 2.0%, miscellaneous genetic disorders for 1.1%, and metabolic disorders for 0.1%. These were not individuals presenting with symptoms. They were a general adult cohort—the population that looks healthy until it isn’t. [DOI: 10.3390/ijms26083509]

That 6.2% figure is not a rounding error. Applied to the executive population PURE serves across Coral Gables, Brickell, Fisher Island, and Miami Beach, it means roughly 1 in 16 individuals undergoing a comprehensive genomic screen will have a finding that directly changes their clinical management—before any symptom has appeared, before any organ system has declared its distress.

Cardiovascular Genetics: What Your DNA Says About Your Heart

Cardiovascular genomics has moved far beyond the question of familial hypercholesterolemia. The 2026 ACC/AHA Multisociety Guideline on Dyslipidemia—published in Current Atherosclerosis Reports—now formally recommends Lp(a) testing at least once in every adult’s lifetime and highlights genetic dyslipidemia screening as a clinical priority. [DOI: 10.1007/s11883-026-01437-9] What the guideline also signals is the broader integration of genetic risk assessment into preventive cardiovascular care—a shift that precision medicine practices have been implementing for years ahead of mainstream adoption.

For atrial fibrillation—the most common sustained cardiac arrhythmia and a leading driver of stroke—genetic risk is now measurable, combinable, and clinically actionable. According to research published in JAMA Cardiology analyzing 416,085 UK Biobank participants, an integrated genomic model combining polygenic risk score, rare monogenic gene variants, and somatic clonal hematopoiesis variants significantly outperformed clinical risk scoring alone (C statistic: 0.80) in predicting five-year atrial fibrillation incidence. The polygenic risk score alone carried a hazard ratio of 1.65 per standard deviation—a meaningful independent predictor of a condition that is often discovered only after a stroke or incidental ECG finding. [DOI: 10.1001/jamacardio.2025.3664]

For executive patients at PURE, this means that a comprehensive cardiovascular genetics assessment—covering polygenic AF risk, inherited cardiomyopathy genes (MYH7, MYBPC3), arrhythmia-associated channelopathies (SCN5A), familial hypercholesterolemia gene variants, and APOE status—provides a layer of risk intelligence that no amount of annual ECGs or lipid panels can replicate. Combined with coronary artery calcium scoring and advanced cardiovascular imaging, the picture becomes genuinely comprehensive.

Hereditary Cancer Risk: What Non-Adherence Costs

For hereditary cancer syndromes—BRCA1/2 for breast and ovarian cancer, MLH1/MSH2 for Lynch syndrome colorectal cancer, PALB2, ATM, and others—the clinical utility of genetic testing is no longer debated. What is debated, and frequently not discussed, is what happens when high-risk individuals are identified but do not follow through on physician-guided risk management.

A 2026 cohort study published in Current Oncology, analyzing 476 BRCA and Lynch syndrome carriers, found that non-adherence to recommended risk management guidelines was associated with 8.70 times greater odds of cancer following genetic testing compared to those who fully adhered (multivariate model, p = 0.0004). Older age at referral was independently associated with increased cancer occurrence. The conclusion is stark: identification of genetic risk without physician-supervised, guideline-adherent follow-through does not produce benefit—it may produce a false sense of security in some patients, and delayed diagnosis in others. [DOI: 10.3390/curroncol33040184]

This is precisely the failure mode of direct-to-consumer genetic testing and unsupervised genomic platforms. They identify variants. They do not coordinate the clinical response. For PURE members in Key Biscayne, Coconut Grove, Pinecrest, and South Miami, every hereditary cancer panel result triggers physician-led discussion, specialist coordination where indicated, and integration with the full imaging and biomarker picture. The identification is only the first step.

Pharmacogenomics: Why Your Medication Response Is Written in Your DNA

Pharmacogenomics is perhaps the most immediately practical application of genetic testing for the executive population—and the most systematically underutilized by standard medicine. Clinical consensus, supported by decades of pharmacogenomic research, establishes several critical gene-drug interactions that affect a significant proportion of the adult population.

CYP2C19 variants determine the activation of clopidogrel, a platelet inhibitor prescribed routinely after cardiac stent procedures. Individuals who are CYP2C19 poor metabolizers cannot adequately activate the drug—a clinically dangerous situation if a standard dose is prescribed without knowing the patient’s metabolizer status. CYP2C19 poor metabolizers make up approximately 2 to 5% of European-ancestry populations and a higher proportion of East Asian-ancestry populations.

SLCO1B1 variants affect statin transport into hepatocytes. The SLCO1B1 c.521T>C variant increases plasma statin exposure and has been associated with up to a 16-fold increase in myopathy risk at high statin doses in certain genotype combinations. For executives on aggressive LDL-lowering protocols—particularly those with high polygenic cardiovascular risk—knowing this variant status before prescribing is not optional. It is foundational to safe medication selection.

VKORC1 variants determine warfarin sensitivity. Patients with the VKORC1 -1639A variant require substantially lower warfarin doses to achieve target anticoagulation—a fact that, if ignored, increases bleeding risk during dose titration. For executives traveling internationally with complex medication schedules, pharmacogenomic knowledge eliminates avoidable adverse events.

These are not rare edge cases. They are common genetic variants affecting millions of adults whose physicians prescribed standard doses because the genomic landscape was unknown.

How Precision Genetics and Body Composition Analysis Integrate With PURE’s Executive Health Assessment in Miami

At PURE Executive Health & Wellness in Coral Gables, genetic testing is not a standalone service. Within a concierge medicine model, it functions as part of a membership-based medical practice integrated into executive health. It is one integrated component of a physician-supervised executive health assessment that also includes clinical VO2 max testing via cardiopulmonary exercise testing, DEXA body composition with visceral fat quantification, full-body MRI with subspecialist radiology interpretation, second-generation epigenetic biological age clocks (GrimAge, DunedinPACE), advanced cardiovascular imaging including coronary artery calcium scoring, comprehensive hormonal profiling, and advanced lipid fractionation with Lp(a) and apolipoprotein B). This is typically an add-on to existing insurance rather than a replacement, so patients may still need coverage for specialist visits or hospitalizations, and these services are generally not available with HMO plans.

Every genetic finding is interpreted by board-certified physicians who have reviewed the complete biomarker and imaging picture. A BRCA2 variant does not exist in isolation—it exists in the context of the whole person, including this patient’s inflammatory biomarkers, this patient’s full-body MRI, this patient’s family history, and this patient’s 20-year trajectory as understood through epigenetic age testing. The clinical response is designed around the individual, not the variant. This model helps ensure more personalized patient care, with each appointment often allowing the time to understand the person in full through longer visits, quicker access to a doctor, shorter wait times, more direct attention, and stronger care coordination across the team.

Patients typically pay a flat annual fee for concierge services, with memberships often ranging from about $1,200 to more than $10,000 per year.

The executives and families served by PURE across Indian Creek, Fisher Island, Brickell, and Coral Gables approach their genomic health the way they approach their financial architecture: with professional guidance, institutional rigor, and a commitment to knowing what others are guessing about. For individuals whose cognitive performance, physical capacity, and professional longevity are not abstractions but operating requirements, that standard is not optional.

If your current physician has not discussed your polygenic cardiovascular risk, your hereditary cancer gene panel, or your pharmacogenomic profile, it may be worth understanding what that picture looks like—before the clinical consequences of not knowing become the reason for the conversation. Practices often limit enrollment to support 24/7 access, preventive care, wellness planning, and long-term relationships that can improve satisfaction, though critics argue this model can create a two-tier system that reduces access for lower-income patients.

Learn more about PURE’s comprehensive executive health assessment and precision diagnostics at purehealthmiami.com. For information about PURE’s services for residents of specific Miami neighborhoods, visit our neighborhood pages for concierge medicine in Coral Gables, Brickell, Miami Beach, Fisher Island, and Key Biscayne.

Frequently Asked Questions About Genetic Testing in Miami and Coral Gables

What does genetic testing reveal that a standard annual physical cannot?

A standard physical detects overt disease. Genetic testing reveals inherited risk architecture: variants in genes like LDLR or PCSK9 that cause familial hypercholesterolemia, BRCA1/2 mutations conferring lifetime breast cancer risk above 70%, APOE4 alleles associated with elevated Alzheimer’s risk, pharmacogenomic variants that determine how you metabolize medications including statins and anticoagulants, and polygenic risk scores for atrial fibrillation and cardiovascular events. Research published in the International Journal of Molecular Sciences (2025) found medically actionable variants in 6.2% of 3,972 individuals screened using the ACMG gene panel—most of whom had no clinical symptoms indicating a problem.

What are the most clinically important genes in a precision genetics panel?

The ACMG v3.2 list identifies 81 actionable genes. For executive health, the most impactful categories are: cardiovascular (LDLR, APOB, PCSK9 for familial hypercholesterolemia; MYH7, MYBPC3 for hypertrophic cardiomyopathy; SCN5A for arrhythmia); cancer predisposition (BRCA1, BRCA2, MLH1, MSH2, APC); pharmacogenomics (CYP2C19 affecting clopidogrel efficacy, VKORC1 affecting warfarin dosing, SLCO1B1 affecting statin-related myopathy risk); and longevity markers including APOE status.

Does genetic testing for cardiovascular risk change clinical management?

Yes. The 2026 ACC/AHA Multisociety Guideline on dyslipidemia now recommends Lp(a) testing at least once in every adult’s lifetime and highlights the importance of screening for genetic dyslipidemias. A high polygenic risk score for atrial fibrillation—validated in a 416,085-participant UK Biobank study in JAMA Cardiology (2025)—carries a hazard ratio of 1.65 per standard deviation and, when combined with rare monogenic and somatic variants, more than doubles five-year cumulative AF incidence. These findings directly change screening intensity, medication choices, and monitoring frequency.

What is the difference between direct-to-consumer and physician-supervised genetic testing?

Direct-to-consumer tests screen a limited number of variants and are not clinically validated to the same standard as laboratory-based next-generation sequencing. They frequently miss actionable variants and cannot be used for medical decision-making. Physician-supervised panels use clinical-grade sequencing against the full ACMG actionable gene list, provide pre- and post-test genetic counseling, integrate findings with your complete biomarker and imaging picture, and translate results into a concrete clinical action plan. A consumer test showing “no increased risk” for BRCA mutations may miss 95% of pathogenic variants.

What is pharmacogenomic testing and why does it matter?

Pharmacogenomics identifies how your genetic variants affect drug metabolism, efficacy, and toxicity. CYP2C19 variants determine whether clopidogrel is activated normally or fails entirely—critical after cardiac stenting. SLCO1B1 variants increase statin-related myopathy risk by up to 16-fold in certain genotypes. VKORC1 variants determine warfarin sensitivity. For executives who may require medication adjustments as part of a cardiovascular prevention program, pharmacogenomic profiling eliminates the trial-and-error process that standard medicine accepts as inevitable.

How does PURE incorporate genetic testing into its executive health assessment?

At PURE Executive Health & Wellness in Coral Gables, Miami, Florida, genetic testing is one integrated component of a comprehensive assessment that also includes clinical VO2 max testing, body composition analysis, full-body MRI, second-generation epigenetic age clocks, advanced cardiovascular imaging, and complete hormonal profiling, with results used to inform exercise recommendations and personalized planning with a registered dietitian at this location. Every genetic finding is interpreted by a board-certified physician in the context of your full biomarker and imaging picture—not as an isolated report—to optimize well being across every stage of life and help manage risk through a whole-person approach. The result is a written longevity blueprint that converts genetic risk into a prioritized, actionable clinical strategy designed to reach individuals where they live and support them through changing health needs.